Executive Summary
GPO Plus Inc reported QQ4 2024 revenue of $1.08 million, up 131% YoY, and gross profit of $0.25 million (gross margin ~23.1%). Despite top-line growth, the quarter delivered a significant operating loss of $1.56 million and a net loss of $1.86 million, translating to an EPS of -$0.043. The results reflect a steep burn on largely fixed costs, material stock-based compensation, and interest burden, culminating in a severely strained liquidity position. The balance sheet shows entrenched negative equity and high short-term indebtedness, with total current liabilities exceeding current assets by a wide margin and a cash balance that dwindled to $69k by period end. The combination of negative profitability, weak liquidity ratios (current ratio ~0.13; quick ratio ~0.038; cash ratio ~0.016) and a heavy debt load creates a high-risk execution environment for GPOX in the near term.
Key Performance Indicators
QoQ: -1.02% | YoY:131.13%
QoQ: 61.97% | YoY:105.28%
QoQ: -108.57% | YoY:-31.39%
QoQ: -110.65% | YoY:-34.76%
QoQ: -115.50% | YoY:-11.66%
Key Insights
Revenue: $1,078,415 (YoY +131.13%; QoQ -1.02%). Gross Profit: $249,506 (YoY +105.28%; QoQ +61.97%). Operating Income: -$1,558,533 (YoY -31.39%; QoQ -108.57%). Net Income: -$1,861,418 (YoY -34.76%; QoQ -110.65%). EPS: -$0.0431 (YoY -11.66%; QoQ -115.50%). Gross Margin: 23.14%; EBITDA: -$1,530,281; EBITDA Margin: -141.90%. Cash from operations: -$378,837; Free Cash Flow: -$378,837. Cash at end of period: $69,415. Current ratio: 0.13; Quick ratio: 0.0377; Cash ratio: 0.0161. Total debt: $2,197,789;...
Financial Highlights
Revenue: $1,078,415 (YoY +131.13%; QoQ -1.02%). Gross Profit: $249,506 (YoY +105.28%; QoQ +61.97%). Operating Income: -$1,558,533 (YoY -31.39%; QoQ -108.57%). Net Income: -$1,861,418 (YoY -34.76%; QoQ -110.65%). EPS: -$0.0431 (YoY -11.66%; QoQ -115.50%). Gross Margin: 23.14%; EBITDA: -$1,530,281; EBITDA Margin: -141.90%. Cash from operations: -$378,837; Free Cash Flow: -$378,837. Cash at end of period: $69,415. Current ratio: 0.13; Quick ratio: 0.0377; Cash ratio: 0.0161. Total debt: $2,197,789; Net debt: $2,128,374. Total stockholders’ equity: -$5,462,826 (negative); Retained earnings: -$39,440,047.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
1.08M |
131.13% |
-1.02% |
| Gross Profit |
249.51K |
105.28% |
61.97% |
| Operating Income |
-1.56M |
-31.39% |
-108.57% |
| Net Income |
-1.86M |
-34.76% |
-110.65% |
| EPS |
-0.04 |
-11.66% |
-115.50% |
Key Financial Ratios
operatingProfitMargin
-144.5%
operatingCashFlowPerShare
$-0.01
freeCashFlowPerShare
$-0.01
Management Commentary
No earnings call transcript data were provided in the dataset. As a result, there are no management quotes available to group by themes (strategy, operations, market conditions) within this QQ4 2024 analysis.
Forward Guidance
Management did not publish formal QQ4 2024 guidance in the provided data. Given the current trajectory, investors should monitor: (1) liquidity runway and the timing/amount of any potential debt restructuring or capital raises; (2) cadence of cost containment, SG&A optimization, and potential SG&A normalization versus growth investments; (3) working capital dynamics (notably inventory buildup and payables timing) to improve cash conversion; (4) progress in revenue diversification across HealthGPO, cbdGPO and any new verticals; (5) debt maturities and covenants, given high short-term indebtedness. Absent concrete guidance, the achievability of a material improvement hinges on meaningful operating leverage from cost discipline and/or accelerated revenue growth in scalable GPO segments.